Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Wolfgang Schuette, Peter Schirmacher, Wilfried E. E. Eberhardt, Manfred Dietel, Ute Zirrgiebel, Lars Muehlenhoff, Michael Thomas

ABSTRACT

BACKGROUND: We evaluated treatment decisions and outcomes in a cohort of predominately Caucasian patients with EGFR mutation-positive (EGFR Mut+) non-small-cell lung cancer (NSCLC). METHODS: REASON (NCT00997230) was a non-interventional study in German patients with stage IIIB/IV NSCLC. Secondary endpoints for EGFR Mut + NSCLC included progression-free survival (PFS), overall survival (OS), adverse event (AE) management, and pharmacoeconomic outcomes. RESULTS: Among 334 patients with EGFR Mut + NSCLC, tyrosine kinase inhibitors (TKIs) were the most common first-line therapy (56.6%, 53.0% gefitinib). Among patients who received TKIs/gefitinib before first disease progression, PFS was longer compared with those who did not receive a TKI (median 10.1/10.0 vs. 7.0 months; HR 0.67/0.69; log-rank p = 0.012/p = 0.022). OS was longer for those patients who ever received a TKI/gefitinib during their complete therapy course compared with those who never received a TKI (median 18.4/18.1 vs. 13.6 months; HR 0.53/0.55; p = 0.003/p = 0.005). Total mean first-line treatment healthcare costs per person were higher for those receiving TKIs (€46,443) compared with those who received chemotherapy (€27,182). Mean outpatient and inpatient costs were highest with chemotherapy. Rash, diarrhea, and dry skin were the most commonly reported AEs for patients receiving gefitinib. CONCLUSIONS: In REASON, TKI therapy was the most common first- and second-line treatment for EGFR Mut + NSCLC, associated with increased drug costs compared with chemotherapy. Patients who received gefitinib or a TKI ever during their complete therapy course had prolonged PFS and OS compared with patients who did not receive a TKI. TRIAL REGISTRATION: The trial was registered on October, 2009 with ClinicalTrials.gov : https://clinicaltrials.gov/ct2/show/NCT00997230?term=NCT00997230&rank=1. More... »

PAGES

135

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-018-4032-3

DOI

http://dx.doi.org/10.1186/s12885-018-4032-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1100822662

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29402243


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diarrhea", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Economics, Pharmaceutical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Exanthema", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Germany", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Outcome Assessment (Health Care)", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinazolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, Epidermal Growth Factor", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Krankenhaus Martha-Maria Halle-Doelau gGmbH, Klinik f\u00fcr Innere Medizin II, Roentgenstr, 106120, Halle, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schuette", 
        "givenName": "Wolfgang", 
        "id": "sg:person.01301122623.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301122623.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital Heidelberg", 
          "id": "https://www.grid.ac/institutes/grid.5253.1", 
          "name": [
            "Pathologisches Institut, Universit\u00e4tklinik Heidelberg, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schirmacher", 
        "givenName": "Peter", 
        "id": "sg:person.01072556301.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072556301.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Medical Oncology, West German Tumor Centre, University Hospital Essen, Rurhlandlkinik, University Duisburg-Essen, Essen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eberhardt", 
        "givenName": "Wilfried E. E.", 
        "id": "sg:person.01141244252.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141244252.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Pathologisches Institut Humboldt, Universit\u00e4t Berlin, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dietel", 
        "givenName": "Manfred", 
        "id": "sg:person.01340546577.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340546577.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Iomedico (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.476932.d", 
          "name": [
            "iOMEDICO AG, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zirrgiebel", 
        "givenName": "Ute", 
        "id": "sg:person.0701531475.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701531475.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.487186.4", 
          "name": [
            "Medical Affairs, AstraZeneca, Wedel, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Muehlenhoff", 
        "givenName": "Lars", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital Heidelberg", 
          "id": "https://www.grid.ac/institutes/grid.5253.1", 
          "name": [
            "Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universit\u00e4tsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thomas", 
        "givenName": "Michael", 
        "id": "sg:person.01371076774.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371076774.35"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/1055-9965.epi-14-1149", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000793506"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds409", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004719581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0810699", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020150048"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/scitranslmed.3006802", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020405360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12253-013-9715-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028108786", 
          "https://doi.org/10.1007/s12253-013-9715-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12253-013-9715-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028108786", 
          "https://doi.org/10.1007/s12253-013-9715-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4143/crt.2013.227", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031831228"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2088", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032628685", 
          "https://doi.org/10.1038/nrc2088"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2012.12.027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036026674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jtho.2016.05.036", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042547455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(11)72456-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043759252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/03007995.2013.860372", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045321803"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0909530", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047104724"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.45.3753", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052635973"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078613529", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw326", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079330771"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "BACKGROUND: We evaluated treatment decisions and outcomes in a cohort of predominately Caucasian patients with EGFR mutation-positive (EGFR Mut+) non-small-cell lung cancer (NSCLC).\nMETHODS: REASON (NCT00997230) was a non-interventional study in German patients with stage IIIB/IV NSCLC. Secondary endpoints for EGFR Mut\u2009+\u2009NSCLC included progression-free survival (PFS), overall survival (OS), adverse event (AE) management, and pharmacoeconomic outcomes.\nRESULTS: Among 334 patients with EGFR Mut\u2009+\u2009NSCLC, tyrosine kinase inhibitors (TKIs) were the most common first-line therapy (56.6%, 53.0% gefitinib). Among patients who received TKIs/gefitinib before first disease progression, PFS was longer compared with those who did not receive a TKI (median 10.1/10.0 vs. 7.0\u00a0months; HR 0.67/0.69; log-rank p\u00a0=\u20090.012/p\u00a0=\u20090.022). OS was longer for those patients who ever received a TKI/gefitinib during their complete therapy course compared with those who never received a TKI (median 18.4/18.1 vs. 13.6\u00a0months; HR 0.53/0.55; p\u00a0=\u20090.003/p\u00a0=\u20090.005). Total mean first-line treatment healthcare costs per person were higher for those receiving TKIs (\u20ac46,443) compared with those who received chemotherapy (\u20ac27,182). Mean outpatient and inpatient costs were highest with chemotherapy. Rash, diarrhea, and dry skin were the most commonly reported AEs for patients receiving gefitinib.\nCONCLUSIONS: In REASON, TKI therapy was the most common first- and second-line treatment for EGFR Mut\u2009+\u2009NSCLC, associated with increased drug costs compared with chemotherapy. Patients who received gefitinib or a TKI ever during their complete therapy course had prolonged PFS and OS compared with patients who did not receive a TKI.\nTRIAL REGISTRATION: The trial was registered on October, 2009 with ClinicalTrials.gov : https://clinicaltrials.gov/ct2/show/NCT00997230?term=NCT00997230&rank=1.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-018-4032-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "name": "Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study", 
    "pagination": "135", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "a1ba0936b15f57dc39be015967be451562ac27191653b5efc11a5eeff5056d64"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29402243"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-018-4032-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1100822662"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-018-4032-3", 
      "https://app.dimensions.ai/details/publication/pub.1100822662"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T13:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8659_00000493.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186/s12885-018-4032-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4032-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4032-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4032-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4032-3'


 

This table displays all metadata directly associated to this object as RDF triples.

252 TRIPLES      21 PREDICATES      65 URIs      42 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-018-4032-3 schema:about N0c6d9be37277474dacd070bfcbe7875f
2 N110dda82edb44961864dbb7e3fa5191b
3 N1b23d8f7744f451faddfbe73fc4d175f
4 N2367bac515a746bc9fdd3d7d3df469df
5 N27e32834569245e2901f77a605c5e23b
6 N3aeade3c5078486283a12a8437c72a57
7 N3f854cc7c9dd49f7b2030bc4c08d3b88
8 N40205a7698e3435d885c683ccdc0d4dd
9 N57b1fca08fda480c8fbb9f7df593d8e6
10 N6b8bb54884274064a6b2b73adc312915
11 N6dd0cd20dbc24fba8a5de9a9840ae156
12 N7ce265d2a58345a08171d721aa5f967d
13 N803dc78ec7bb4dabbabae580fd816b98
14 N9622ac809cd2407fbec4ae5662676c80
15 N9800b457ade14b8fbdb07ecf24cbcb88
16 Na0598959a28943c5a2483aa4645ce62a
17 Na5bf3c04c58a4d2fbce23880658348a9
18 Nb925404c6af14f4099ae71fcc83d8632
19 Ndf092de2860445f9b271feed79f75aa9
20 Neeb40ddffcdb460aa5eb442364492d5c
21 Nef50a9d5f2a848a0b6d6ff2230304287
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author Nba807fb8af8f4b899ead46cccb34d72e
25 schema:citation sg:pub.10.1007/s12253-013-9715-0
26 sg:pub.10.1038/nrc2088
27 https://app.dimensions.ai/details/publication/pub.1078613529
28 https://doi.org/10.1016/j.ejca.2012.12.027
29 https://doi.org/10.1016/j.jtho.2016.05.036
30 https://doi.org/10.1016/s0959-8049(11)72456-x
31 https://doi.org/10.1056/nejmoa0810699
32 https://doi.org/10.1056/nejmoa0909530
33 https://doi.org/10.1093/annonc/mds409
34 https://doi.org/10.1093/annonc/mdw326
35 https://doi.org/10.1126/scitranslmed.3006802
36 https://doi.org/10.1158/1055-9965.epi-14-1149
37 https://doi.org/10.1185/03007995.2013.860372
38 https://doi.org/10.1200/jco.2012.45.3753
39 https://doi.org/10.4143/crt.2013.227
40 schema:datePublished 2018-12
41 schema:datePublishedReg 2018-12-01
42 schema:description BACKGROUND: We evaluated treatment decisions and outcomes in a cohort of predominately Caucasian patients with EGFR mutation-positive (EGFR Mut+) non-small-cell lung cancer (NSCLC). METHODS: REASON (NCT00997230) was a non-interventional study in German patients with stage IIIB/IV NSCLC. Secondary endpoints for EGFR Mut + NSCLC included progression-free survival (PFS), overall survival (OS), adverse event (AE) management, and pharmacoeconomic outcomes. RESULTS: Among 334 patients with EGFR Mut + NSCLC, tyrosine kinase inhibitors (TKIs) were the most common first-line therapy (56.6%, 53.0% gefitinib). Among patients who received TKIs/gefitinib before first disease progression, PFS was longer compared with those who did not receive a TKI (median 10.1/10.0 vs. 7.0 months; HR 0.67/0.69; log-rank p = 0.012/p = 0.022). OS was longer for those patients who ever received a TKI/gefitinib during their complete therapy course compared with those who never received a TKI (median 18.4/18.1 vs. 13.6 months; HR 0.53/0.55; p = 0.003/p = 0.005). Total mean first-line treatment healthcare costs per person were higher for those receiving TKIs (€46,443) compared with those who received chemotherapy (€27,182). Mean outpatient and inpatient costs were highest with chemotherapy. Rash, diarrhea, and dry skin were the most commonly reported AEs for patients receiving gefitinib. CONCLUSIONS: In REASON, TKI therapy was the most common first- and second-line treatment for EGFR Mut + NSCLC, associated with increased drug costs compared with chemotherapy. Patients who received gefitinib or a TKI ever during their complete therapy course had prolonged PFS and OS compared with patients who did not receive a TKI. TRIAL REGISTRATION: The trial was registered on October, 2009 with ClinicalTrials.gov : https://clinicaltrials.gov/ct2/show/NCT00997230?term=NCT00997230&rank=1.
43 schema:genre research_article
44 schema:inLanguage en
45 schema:isAccessibleForFree true
46 schema:isPartOf N0138fe03dccd4a1bb596908b78e47eb9
47 N6b575c59cd3345ff99234a639e324684
48 sg:journal.1024632
49 schema:name Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study
50 schema:pagination 135
51 schema:productId N859aa879d22142d9a1b56f1d8154784d
52 Na1a8da5293d542e7aaf833cf8efcc87d
53 Nb38f9efb91314ad990d169c4f1fd1f82
54 Ncdc6d3038706475cbc4f61bd94d03f17
55 Nf5ef610c71d94f62bf885de11e0e4cdc
56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100822662
57 https://doi.org/10.1186/s12885-018-4032-3
58 schema:sdDatePublished 2019-04-10T13:10
59 schema:sdLicense https://scigraph.springernature.com/explorer/license/
60 schema:sdPublisher N331e00f5370c44f4bd4455610fec2577
61 schema:url http://link.springer.com/10.1186/s12885-018-4032-3
62 sgo:license sg:explorer/license/
63 sgo:sdDataset articles
64 rdf:type schema:ScholarlyArticle
65 N0138fe03dccd4a1bb596908b78e47eb9 schema:issueNumber 1
66 rdf:type schema:PublicationIssue
67 N0c6d9be37277474dacd070bfcbe7875f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Prospective Studies
69 rdf:type schema:DefinedTerm
70 N0db525b9e22c47d3a6d07ebac2eb662d rdf:first sg:person.01141244252.56
71 rdf:rest N492b0dc44d394603a9c2d72116d89c0d
72 N110dda82edb44961864dbb7e3fa5191b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Protein Kinase Inhibitors
74 rdf:type schema:DefinedTerm
75 N19536d532f0f420484cb65487c8cb318 schema:name Pathologisches Institut Humboldt, Universität Berlin, Berlin, Germany
76 rdf:type schema:Organization
77 N1b23d8f7744f451faddfbe73fc4d175f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Disease-Free Survival
79 rdf:type schema:DefinedTerm
80 N2367bac515a746bc9fdd3d7d3df469df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Germany
82 rdf:type schema:DefinedTerm
83 N27e32834569245e2901f77a605c5e23b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Aged, 80 and over
85 rdf:type schema:DefinedTerm
86 N2c913fcec79a4b11ab0fc184e9c3ae12 rdf:first Nec7768d3970446bda2a44c2866f36431
87 rdf:rest N8e3c3dafad51495291db1c6b84490e9f
88 N331e00f5370c44f4bd4455610fec2577 schema:name Springer Nature - SN SciGraph project
89 rdf:type schema:Organization
90 N36949327d62b4e758a9def02f25167a0 schema:name Department of Medical Oncology, West German Tumor Centre, University Hospital Essen, Rurhlandlkinik, University Duisburg-Essen, Essen, Germany
91 rdf:type schema:Organization
92 N3aeade3c5078486283a12a8437c72a57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Quinazolines
94 rdf:type schema:DefinedTerm
95 N3f854cc7c9dd49f7b2030bc4c08d3b88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Diarrhea
97 rdf:type schema:DefinedTerm
98 N40205a7698e3435d885c683ccdc0d4dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Male
100 rdf:type schema:DefinedTerm
101 N492b0dc44d394603a9c2d72116d89c0d rdf:first sg:person.01340546577.39
102 rdf:rest Ne7972b4d58d54635981af8120b2e1a33
103 N57b1fca08fda480c8fbb9f7df593d8e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Economics, Pharmaceutical
105 rdf:type schema:DefinedTerm
106 N6b575c59cd3345ff99234a639e324684 schema:volumeNumber 18
107 rdf:type schema:PublicationVolume
108 N6b8bb54884274064a6b2b73adc312915 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Humans
110 rdf:type schema:DefinedTerm
111 N6dd0cd20dbc24fba8a5de9a9840ae156 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Outcome Assessment (Health Care)
113 rdf:type schema:DefinedTerm
114 N7ce265d2a58345a08171d721aa5f967d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Aged
116 rdf:type schema:DefinedTerm
117 N803dc78ec7bb4dabbabae580fd816b98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Middle Aged
119 rdf:type schema:DefinedTerm
120 N859aa879d22142d9a1b56f1d8154784d schema:name doi
121 schema:value 10.1186/s12885-018-4032-3
122 rdf:type schema:PropertyValue
123 N8e3c3dafad51495291db1c6b84490e9f rdf:first sg:person.01371076774.35
124 rdf:rest rdf:nil
125 N9622ac809cd2407fbec4ae5662676c80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Receptor, Epidermal Growth Factor
127 rdf:type schema:DefinedTerm
128 N9800b457ade14b8fbdb07ecf24cbcb88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Mutation
130 rdf:type schema:DefinedTerm
131 Na0598959a28943c5a2483aa4645ce62a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Lung Neoplasms
133 rdf:type schema:DefinedTerm
134 Na1a8da5293d542e7aaf833cf8efcc87d schema:name readcube_id
135 schema:value a1ba0936b15f57dc39be015967be451562ac27191653b5efc11a5eeff5056d64
136 rdf:type schema:PropertyValue
137 Na5bf3c04c58a4d2fbce23880658348a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Female
139 rdf:type schema:DefinedTerm
140 Nb38f9efb91314ad990d169c4f1fd1f82 schema:name pubmed_id
141 schema:value 29402243
142 rdf:type schema:PropertyValue
143 Nb925404c6af14f4099ae71fcc83d8632 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Carcinoma, Non-Small-Cell Lung
145 rdf:type schema:DefinedTerm
146 Nba807fb8af8f4b899ead46cccb34d72e rdf:first sg:person.01301122623.31
147 rdf:rest Nbc036cdd47054bcc9b64bdc5c7538436
148 Nbc036cdd47054bcc9b64bdc5c7538436 rdf:first sg:person.01072556301.62
149 rdf:rest N0db525b9e22c47d3a6d07ebac2eb662d
150 Ncdc6d3038706475cbc4f61bd94d03f17 schema:name nlm_unique_id
151 schema:value 100967800
152 rdf:type schema:PropertyValue
153 Ndf092de2860445f9b271feed79f75aa9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Adult
155 rdf:type schema:DefinedTerm
156 Ne0fb4e3b1de84fb0a0ec9129bb54b38c schema:name Krankenhaus Martha-Maria Halle-Doelau gGmbH, Klinik für Innere Medizin II, Roentgenstr, 106120, Halle, Germany
157 rdf:type schema:Organization
158 Ne7972b4d58d54635981af8120b2e1a33 rdf:first sg:person.0701531475.61
159 rdf:rest N2c913fcec79a4b11ab0fc184e9c3ae12
160 Nec7768d3970446bda2a44c2866f36431 schema:affiliation https://www.grid.ac/institutes/grid.487186.4
161 schema:familyName Muehlenhoff
162 schema:givenName Lars
163 rdf:type schema:Person
164 Neeb40ddffcdb460aa5eb442364492d5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Neoplasm Staging
166 rdf:type schema:DefinedTerm
167 Nef50a9d5f2a848a0b6d6ff2230304287 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Exanthema
169 rdf:type schema:DefinedTerm
170 Nf5ef610c71d94f62bf885de11e0e4cdc schema:name dimensions_id
171 schema:value pub.1100822662
172 rdf:type schema:PropertyValue
173 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
174 schema:name Medical and Health Sciences
175 rdf:type schema:DefinedTerm
176 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
177 schema:name Oncology and Carcinogenesis
178 rdf:type schema:DefinedTerm
179 sg:journal.1024632 schema:issn 1471-2407
180 schema:name BMC Cancer
181 rdf:type schema:Periodical
182 sg:person.01072556301.62 schema:affiliation https://www.grid.ac/institutes/grid.5253.1
183 schema:familyName Schirmacher
184 schema:givenName Peter
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072556301.62
186 rdf:type schema:Person
187 sg:person.01141244252.56 schema:affiliation N36949327d62b4e758a9def02f25167a0
188 schema:familyName Eberhardt
189 schema:givenName Wilfried E. E.
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141244252.56
191 rdf:type schema:Person
192 sg:person.01301122623.31 schema:affiliation Ne0fb4e3b1de84fb0a0ec9129bb54b38c
193 schema:familyName Schuette
194 schema:givenName Wolfgang
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301122623.31
196 rdf:type schema:Person
197 sg:person.01340546577.39 schema:affiliation N19536d532f0f420484cb65487c8cb318
198 schema:familyName Dietel
199 schema:givenName Manfred
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340546577.39
201 rdf:type schema:Person
202 sg:person.01371076774.35 schema:affiliation https://www.grid.ac/institutes/grid.5253.1
203 schema:familyName Thomas
204 schema:givenName Michael
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371076774.35
206 rdf:type schema:Person
207 sg:person.0701531475.61 schema:affiliation https://www.grid.ac/institutes/grid.476932.d
208 schema:familyName Zirrgiebel
209 schema:givenName Ute
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701531475.61
211 rdf:type schema:Person
212 sg:pub.10.1007/s12253-013-9715-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028108786
213 https://doi.org/10.1007/s12253-013-9715-0
214 rdf:type schema:CreativeWork
215 sg:pub.10.1038/nrc2088 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032628685
216 https://doi.org/10.1038/nrc2088
217 rdf:type schema:CreativeWork
218 https://app.dimensions.ai/details/publication/pub.1078613529 schema:CreativeWork
219 https://doi.org/10.1016/j.ejca.2012.12.027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036026674
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1016/j.jtho.2016.05.036 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042547455
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1016/s0959-8049(11)72456-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043759252
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1056/nejmoa0810699 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020150048
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1056/nejmoa0909530 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047104724
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1093/annonc/mds409 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004719581
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1093/annonc/mdw326 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079330771
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1126/scitranslmed.3006802 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020405360
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1158/1055-9965.epi-14-1149 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000793506
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1185/03007995.2013.860372 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045321803
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1200/jco.2012.45.3753 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052635973
240 rdf:type schema:CreativeWork
241 https://doi.org/10.4143/crt.2013.227 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031831228
242 rdf:type schema:CreativeWork
243 https://www.grid.ac/institutes/grid.476932.d schema:alternateName Iomedico (Germany)
244 schema:name iOMEDICO AG, Freiburg, Germany
245 rdf:type schema:Organization
246 https://www.grid.ac/institutes/grid.487186.4 schema:alternateName AstraZeneca (Germany)
247 schema:name Medical Affairs, AstraZeneca, Wedel, Germany
248 rdf:type schema:Organization
249 https://www.grid.ac/institutes/grid.5253.1 schema:alternateName University Hospital Heidelberg
250 schema:name Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research, Heidelberg, Germany
251 Pathologisches Institut, Universitätklinik Heidelberg, Heidelberg, Germany
252 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...